These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 14598506)

  • 21. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
    Hørslev-Petersen K; Hetland ML; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2014 Apr; 73(4):654-61. PubMed ID: 23434570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).
    Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS
    J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
    Malysheva OA; Wahle M; Wagner U; Pierer M; Arnold S; Häntzschel H; Baerwald CG
    J Rheumatol; 2008 Jun; 35(6):979-85. PubMed ID: 18412314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Therapy of refractory rheumatoid arthritis. Cyclosporin and methotrexate combination].
    Danieli MG; Fratini M; Rossetti L; Giovagnoni A; Amici F; Danieli G
    Recenti Prog Med; 1998 Jan; 89(1):7-13. PubMed ID: 9549386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis.
    Cummins L; Katikireddi VS; Shankaranarayana S; Su KY; Duggan E; Videm V; Pahau H; Thomas R
    Intern Med J; 2015 Dec; 45(12):1266-73. PubMed ID: 26384029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of small-dose glucocorticoids on the course of early rheumatic arthritis].
    Suponitskaia EV; Smirnov AV; Aleksandrova EN; Novikov AA; Nasonov EL
    Klin Med (Mosk); 2004; 82(9):39-42. PubMed ID: 15540421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of two schedules for administering oral low-dose methotrexate (weekly versus every-other-week) in patients with rheumatoid arthritis in remission: a twenty-four week, single blind, randomized study.
    Luis M; Pacheco-Tena C; Cazarín-Barrientos J; Lino-Pérez L; Goycochea MV; Vazquez-Mellado J; Burgos-Vargas R
    Arthritis Rheum; 1999 Oct; 42(10):2160-5. PubMed ID: 10524688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pneumocystis pneumonia -- atypical manifestation in an immunosuppressed patient with rheumatoid arthritis].
    Tschampa HJ; Sommer T; Tasci S
    Rofo; 2004 Dec; 176(12):1845-6. PubMed ID: 15573299
    [No Abstract]   [Full Text] [Related]  

  • 30. Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients.
    Valleala H; Korpela M; Möttönen T; Hienonen-Kempas T; Kauppi M; Hannonen P; Leirisalo-Repo M
    Scand J Rheumatol; 2009; 38(5):323-7. PubMed ID: 19585384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis: results of an open study to assess feasibility, safety, and efficacy.
    Verburg RJ; Kruize AA; van den Hoogen FH; Fibbe WE; Petersen EJ; Preijers F; Sont JK; Barge RM; Bijlsma JW; van de Putte LB; Breedveld FC; van Laar JM
    Arthritis Rheum; 2001 Apr; 44(4):754-60. PubMed ID: 11315914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Remission induction after pentoxifylline treatment in a patient with rheumatoid arthritis].
    Ishii O; Yamada H; Ohya S; Moriuchi E; Kase C; Ichikawa Y; Yamasaki K
    Ryumachi; 1997 Dec; 37(6):810-5. PubMed ID: 9492569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Combination therapy in early rheumatoid arthritis: the COBRA study].
    Boers M; Verhoeven AC; van der Linden S
    Ned Tijdschr Geneeskd; 1997 Dec; 141(50):2428-32. PubMed ID: 9555126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs.
    Cantini F; Niccoli L; Nannini C; Cassarà E; Pasquetti P; Olivieri I; Salvarani C
    Rheumatology (Oxford); 2008 Jun; 47(6):872-6. PubMed ID: 18400836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modern treatment strategies in rheumatoid arthritis.
    Hetland ML
    Dan Med Bull; 2011 Nov; 58(11):B4320. PubMed ID: 22047935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial.
    Saevarsdottir S; Wallin H; Seddighzadeh M; Ernestam S; Geborek P; Petersson IF; Bratt J; van Vollenhoven RF;
    Ann Rheum Dis; 2011 Mar; 70(3):469-75. PubMed ID: 21149498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
    Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J
    Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.
    Vermeer M; Kuper HH; Hoekstra M; Haagsma CJ; Posthumus MD; Brus HL; van Riel PL; van de Laar MA
    Arthritis Rheum; 2011 Oct; 63(10):2865-72. PubMed ID: 21647867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years.
    Strand V; Balbir-Gurman A; Pavelka K; Emery P; Li N; Yin M; Lehane PB; Agarwal S
    Rheumatology (Oxford); 2006 Dec; 45(12):1505-13. PubMed ID: 17062648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.